{
  "title": "New Somatic Treatments for Child and Adolescent Depression",
  "itunes:title": "New Somatic Treatments for Child and Adolescent Depression",
  "pubDate": "Wed, 25 Aug 2021 16:00:00 +0000",
  "guid": "33df8d2a-fd7e-429d-afef-9c1ce70e75eb",
  "link": "https://psychopharmacology.libsyn.com/new-somatic-treatments-for-child-and-adolescent-depression",
  "itunes:image": "",
  "description": "<p>First-line treatments for child and adolescent depression are cognitive–behavioral therapy, interpersonal therapy, fluoxetine, and escitalopram.<br /> What works besides routine first-line approaches? This episode discusses options to consider: Pharmaceuticals, nutraceuticals, somatomotor techniques (e.g., yoga), and neuromodulatory tools (e.g., ECT and TMS).</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= \"https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106\"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= \"https://psychopharmacologyinstitute.com/publication/quick-take-vol-25-2578?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106\"> <strong>Earn 0.5 CMEs: Quick Take Vol. 25</strong></a></li> <li><a href= \"https://psychopharmacologyinstitute.com/section/new-somatic-treatments-for-child-and-adolescent-depression-part-1-2578-5017?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106\"> <strong>New Somatic Treatments for Child and Adolescent Depression (Part 1) </strong></a></li> </ul>",
  "content:encoded": "<p>First-line treatments for child and adolescent depression are cognitive–behavioral therapy, interpersonal therapy, fluoxetine, and escitalopram. What works besides routine first-line approaches? This episode discusses options to consider: Pharmaceuticals, nutraceuticals, somatomotor techniques (e.g., yoga), and neuromodulatory tools (e.g., ECT and TMS).</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= \"https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106\"> Learn more about our memberships here</a></li> <li><a href= \"https://psychopharmacologyinstitute.com/publication/quick-take-vol-25-2578?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106\"> Earn 0.5 CMEs: Quick Take Vol. 25</a></li> <li><a href= \"https://psychopharmacologyinstitute.com/section/new-somatic-treatments-for-child-and-adolescent-depression-part-1-2578-5017?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC106\"> New Somatic Treatments for Child and Adolescent Depression (Part 1) </a></li> </ul>",
  "enclosure": "",
  "itunes:duration": "10:02",
  "itunes:explicit": false,
  "itunes:keywords": "",
  "itunes:subtitle": "First-line treatments for child and adolescent depression are cognitive–behavioral therapy, interpersonal therapy, fluoxetine, and escitalopram. What works besides routine first-line approaches? This episode discusses options to consider:...",
  "itunes:episodeType": "full"
}